{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:28:55Z","timestamp":1789950535769,"version":"4.0.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"\n Background:<\/jats:title>\n The present study tries to compare the unintended outcomes of the Catania stent versus Xience stent in patients undergoing angioplasty.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n In a three month, follow-up, double-blinded, randomized controlled trial, 83 patients undergoing angioplasty, who met the inclusion criteria were entered into the study. After randomization 43 patients were treated with the Xience stent and 40 patients with the Catania stent. Stent-related outcomes such as Cardiac and Non-Cardiovascular Death, Myocardial Infarction (MI), Target Lesion Revascularization (TLR), Stent Thrombosis (ST), Coronary Artery Bypass Grafting (CABG), Peripheral vasculopathy, and Cerebral Vascular Accident (CVA) were compared between the groups.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n There was no statistically significant difference in the incidence rate of complications and clinical outcomes between the two treatment groups (\n P<\/jats:italic>\n > 0.05). The incidence of MI, TLR, CABG operation, peripheral vasculopathy, or CVA was not observed in any patient and there was no statistically difference in mortality (4.7% vs. 2.5%;\n P<\/jats:italic>\n = 0.527) and stent thrombosis (2.3% vs. 2.5%;\n P<\/jats:italic>\n = 0.735).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n All in all, the present study could not find the significant differences between the Catania stent and Xience stent in terms of clinical outcomes during the follow-up period.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/2277-9175.219419","type":"journal-article","created":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T01:41:47Z","timestamp":1511919707000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Undesired Outcomes of the Catania Stent Compared to the Xience Stent in Patients Undergoing Angioplasty: A Double-Blind Randomized Controlled Trial"],"prefix":"10.4103","volume":"6","author":[{"given":"Masoud","family":"Pourmoghaddas","sequence":"first","affiliation":[{"name":"From the Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza","family":"Rohani","sequence":"additional","affiliation":[{"name":"From the Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Sanei","sequence":"additional","affiliation":[{"name":"Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Amirpour","sequence":"additional","affiliation":[{"name":"From the Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,11,30]]},"reference":[{"key":"R1-20250806","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/vhrm.2005.1.4.263","article-title":"Drug-eluting stent: A review and update","volume":"1","author":"Htay","year":"2005","journal-title":"Vasc Health Risk Manag"},{"key":"R2-20250806","first-page":"1089","article-title":"Update on the everolimus-eluting coronary stent system: Results and implications from the SPIRIT clinical trial program","volume":"5","author":"Kirchner","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"R3-20250806","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa032441","article-title":"A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease","volume":"350","author":"Stone","year":"2004","journal-title":"N Engl J Med"},{"key":"R4-20250806","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/vhrm.2005.1.4.263","article-title":"Drug-eluting stent: A review and update","volume":"1","author":"Htay","year":"2005","journal-title":"Vasc Health Risk Manag"},{"key":"R5-20250806","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jcin.2008.12.006","article-title":"First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: The ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial","volume":"2","author":"Tamburino","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"R6-20250806","first-page":"103","article-title":"Novel drug-eluting stents in the treatment of de novo coronary lesions","volume":"7","author":"Capodanno","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"R7-20250806","first-page":"54","article-title":"Late stent thrombosis--the \u201cvulnerable\u201d stent","volume":"70","author":"Waksman","year":"2007","journal-title":"Catheter Cardiovasc Interv"},{"key":"R8-20250806","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1161\/01.CIR.0000129767.45513.71","article-title":"Impact of Sirolimus-Eluting Stents on Outcome in Diabetic Patients A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) Substudy","volume":"109","author":"Moussa","year":"2004","journal-title":"Circulation"},{"key":"R9-20250806","first-page":"310","article-title":"Long-term clinical benefit of drug-eluting stents over bare-metal stents in diabetic patients with de novo left main coronary artery disease: Results from a real-world multicenter registry","volume":"73","author":"Capodanno","year":"2009","journal-title":"Catheter Cardiovasc Interv"},{"key":"R10-20250806","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jama.294.10.1215","article-title":"Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease","volume":"294","author":"Stone","year":"2005","journal-title":"JAMA"},{"key":"R11-20250806","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/vhrm.2008.04.01.31","article-title":"Next-generation drug-eluting stents in coronary artery disease: Focus on everolimus-eluting stent (Xience V)","volume":"4","author":"Sheiban","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"R12-20250806","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jacc.2009.05.016","article-title":"The everolimus-eluting stent in real-world patients 6-month follow-up of the X-SEARCH (Xience V) stent evaluated at Rotterdam Cardiac Hospital registry","volume":"54","author":"Onuma","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R13-20250806","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jacc.2012.11.015","article-title":"Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World PracticePatient-Related and Stent-Related Outcomes From the Multicenter Prospective EXCELLENT AND RESOLUTE-Korea Registries","volume":"61","author":"Park","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R14-20250806","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jacc.2011.02.023","article-title":"2-Year Follow-Up of a Randomized Controlled Trial of Everolimus-and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice COMPARE (Comparison of the everolimus eluting Xience-V stent with the paclitaxel eluting TAXUS LIBERT\u00c9 stent in all-comers: A randomized open label trial)","volume":"58","author":"Smits","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R15-20250806","first-page":"286","article-title":"A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial","volume":"2","author":"Serruys","year":"2006","journal-title":"EuroIntervention"},{"key":"R16-20250806","first-page":"58","article-title":"A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The Spirit first trial","volume":"1","author":"Serruys","year":"2005","journal-title":"EuroIntervention"},{"key":"R17-20250806","first-page":"141","article-title":"Do the New Data on Second-Generation drug eluting stents provide reassurance on safety, Efficacy, Even for Off-Label Use?","volume":"5","author":"Iakovou","year":"2010","journal-title":"Hosp Chron"},{"key":"R18-20250806","first-page":"515","article-title":"Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials","volume":"70","author":"Tanimoto","year":"2007","journal-title":"Catheter Cardiovasc Interv"},{"key":"R19-20250806","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1093\/eurheartj\/ehl282","article-title":"Mortality in randomized controlled trials comparing drug-eluting vs.bare metal stents in coronary artery disease: A meta-analysis","volume":"27","author":"Nordmann","year":"2006","journal-title":"Eur Heart J"},{"key":"R20-20250806","first-page":"1062","article-title":"Safety and effectiveness of the Catania Polyzene-F coated stent in real world clinical practice: 12-month results from the Atlanta 2 registry","volume":"7","author":"Tamburino","year":"2012","journal-title":"Euro Intervention"},{"key":"R21-20250806","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2288-4-26","article-title":"Random allocation software for parallel group randomized trials","volume":"4","author":"Saghaei","year":"2004","journal-title":"BMC Med Res Methodol"},{"key":"R22-20250806","first-page":"969","article-title":"Stent thrombosis","volume":"56","author":"Gupta","year":"2008","journal-title":"J Assoc Physicians India"},{"key":"R23-20250806","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1161\/01.CIR.0000127105.99982.21","article-title":"Stent thrombosis after successful sirolimus-eluting stent implantation","volume":"109","author":"Jeremias","year":"2004","journal-title":"Circulation"},{"key":"R24-20250806","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1161\/01.CIR.0000116202.41966.D4","article-title":"Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent should we be cautious?","volume":"109","author":"Virmani","year":"2004","journal-title":"Circulation"}],"container-title":["Advanced Biomedical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01679891-201706000-00154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:48:46Z","timestamp":1787773726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01679891-201706000-00154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/2277-9175.219419","relation":{},"ISSN":["2277-9175"],"issn-type":[{"value":"2277-9175","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"2013-06-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-01-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}